71827-03-7

71827-03-7 structure

Name: Ivermectin B1a
Chemical Name: 22,23-dihydroavermectin B1a
CAS Number: 71827-03-7
Molecular Formula: C₄₈H₇₄O₁₄
Molecular Weight: 875.09300
Catalog: Signaling Pathways Anti-infection SARS-CoV
Create Date: 2016-08-27 11:04:11
Modify Date: 2025-09-18 18:22:08
Ivermectin B1a, a derivative of Avermectin B1a (HY-15308), is a main component of Ivermectin (HY-15310)[1]. Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19[2].

Name	22,23-dihydroavermectin B1a
Synonyms	Prestwick_516

Description	Ivermectin B1a, a derivative of Avermectin B1a (HY-15308), is a main component of Ivermectin (HY-15310)[1]. Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19[2].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Anti-infection >> SARS-CoV
In Vitro	Ivermectin belongs to the macrocyclic lactone class of avermectins and consists of a mixture of two homologous compounds, ivermectin B1a (not less than 80%) and ivermectin B1b (not more than 20%). Ivermectin B1a, the major component of Ivermectin, is inactive at a concentration of 0.3 μg/ml, whereas in the case of the minor component, ivermectin B1b, the same concentration produces 100% mortality of snails[1].
References	[1]. Naftale Kat, et al. Ivermectin Efficacy Against Biomphalaria, Intermediate Host Snail Vectors of Schistosomiasis. J Antibiot (Tokyo). 2017 May;70(5):680-684. [2]. Khan Sharun, et al. Ivermectin, a New Candidate Therapeutic Against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020 May 30;19(1):23.